** Shares of biotechnology company Immutep IMM.AX rise as much as 2.2% to A$0.348, their highest since Nov. 14
** Co has announced initiation of phase-3 trial for the treatment of first-line metastatic non-small cell lung cancer (1L NSCLC)
** Says trial will include over 150 clinical sites in over 25 countries
** Co expects to enrol the first patient in Q1 of CY2025.
** Stock has fallen 0.5% YTD, as of last close
(Reporting by Nichiket Sunil in Bengaluru)
((Nichiket.Sunil@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。